Background and Purpose-Immunodepression after stroke is associated with complications like high infection rate, but its role in aneurysmal subarachnoid hemorrhage (aSAH) is unclear. This pilot study aimed to assess the presence of immunodepression and its association with infections after aSAH. Methods-Sixteen aSAH patients were enrolled in a prospective study on immune function in a single institution. Detailed immune monitoring (peripheral blood leukocyte subsets, monocyte human leukocyte antigen-DR expression, ex vivo lipopolysaccharide-induced monocytic, Concanavalin A-induced lymphocytic cytokine secretion) was performed until day 10 after aSAH. Occurrence of infection was assessed within 14 days after aSAH. Results-Sixteen consecutive aSAH patients (53.1Ϯ10.2 years; meanϮSD) met the inclusion criteria, classified as asymptomatic (World Federation of Neurological Surgeons; median, 1; quartile, 1-1; nϭ7) and symptomatic (median, 4; quartile, 3-5; nϭ9), all presenting with acute neurological deficits, and 5 of these had additional delayed cerebral ischemia. T-lymphopenia, impaired ex vivo lymphocytic/monocytic cytokine secretion, and decreased monocyte human leukocyte antigen-DR expression occurred over all World Federation of Neurological Surgeons grades but persisted beyond day 3 only in symptomatic patients. Pneumonia (67%; Pϭ0.011) was more frequent in symptomatic patients. Already at day 1, patients with pneumonia showed significantly lower T-cell counts and mitogen-induced interferon-␥ production compared to patients without infections. Conclusions-A pronounced SAH-induced immunodepression was observed early after aSAH but persisted only in symptomatic patients. Immunodepression was associated with a high incidence of pneumonia. Early diagnosis of immunodepression might allow targeted treatment to prevent infectious complications after aSAH. (Stroke. 2011;42:53-58.)
A cute aneurysmal subarachnoid hemorrhage (aSAH) is a complex and potentially devastating disorder with high mortality. 1 In addition to the primary effect of the hemorrhage and neurological complications, medical events such as fever, anemia, hyperglycemia, and pneumonia have been identified to correlate with poor outcome in aSAH patients. 2, 3 There is increasing evidence that a temporary impairment of cellular immune function after acute central nervous system injury, such as stroke and traumatic brain injury, represents an important risk factor for the occurrence of infections, particularly pneumonia. 4 -9 Pneumonia is described in 20% of aSAH patients and is associated with a 3-fold increased risk of death at 30 days for acute stroke patients. 10 The occurrence of systemic infections after aSAH may be a symptom of impaired immune competence. In this pilot study, we sought to assess the presence of immunodepression in aSAH patients, with its consequences in terms of bacterial infections aggravating the clinical course.
Materials and Methods

Patient Population
This study was approved by the Local Research Ethics Committee at Charité Virchow Medical Center, in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patient or nearest family relative.
Between January and August 2007, 16 consecutive aSAH patients were enrolled in a prospective study on cerebral metabolism and immune function. The inclusion criteria were: (1) aSAH confirmed by cranial CT; (2) cerebral angiogram demonstrating intracranial aneurysm; and (3) surgical therapy. Clinical presentation was graded according to the World Federation of Neurological Surgeons (WFNS). 11 Aneurysm location was assessed using 4-vessel angiography or CT angiography or both on the day of admission. The distribution and pattern of the hemorrhage were graded as proposed by Fisher. 12 Because cerebral metabolism and, possibly, the inflammatory response are influenced by the presence of concomitant intracerebral hemorrhage or ischemia, patients were categorized as asymptomatic or symptomatic (detailed definitions described previously 13 ) according to their initial neurological state and clinical course. Asymptom-atic aSAH patients presented with only minor symptoms such as headache and no neurological deficits on admission and during the hospital stay. Symptomatic patients presented with acute focal neurological deficits.
The diagnosis of acute focal neurological deficits was based on clinical symptoms (such as hemiparesis) at onset of aSAH related to the initial hemorrhage with corresponding CT findings. Patients with acute deficits were classified as having acute focal neurological deficits, even when delayed cerebral ischemia (DCI) developed later on. These patients typically present with a high WFNS grade and show impaired vigilance, making neurological evaluation difficult. Because their outcome is poor, acute focal neurological deficits patients are probably those who profit most from invasive monitoring. They can have additional DCI as a secondary complication, which can be difficult to detect.
Symptomatic aSAH Patients Presenting With DCI
DCI was defined as symptomatic vasospasm, infarction attributable to vasospasm, or both. 14 The diagnosis of DCI was established after exclusion of other mechanisms such as hydrocephalus or rebleeding and confirmed in (CT) angiography or transcranial Doppler sonography (Doppler ultrasound device EME TC2-64) or both.
In detail, DCI was defined as the occurrence of new focal neurological symptoms, deterioration in level of consciousness, or both, when this was assumed to be caused by vasospasm-induced ischemia. This was the case when other possible causes of worsening (eg, hydrocephalus) had been ruled out and vessel narrowing was confirmed by control angiography or transcranial Doppler sonography. An increase in mean blood flow velocity in transcranial Doppler sonography by Ͼ50% within 24 hours was regarded as pathological; alternatively, a mean blood flow velocity of Ͼ200 cm/sec or a Lindegaard index Ͼ3 were accepted as signs of vasospasm. 15 In poor-grade cases in which neurological examination was limited, DCI was diagnosed in case of new infarctions present in cranial CT or MRI when the cause was assumed to be attributable to vasospasm, as described by Frontera et al. 14 Demographic data are summarized in Table 2 .
Clinical Management
The management of patients with aSAH in the intensive care unit has been described in detail previously. 13 After preoperative resuscitation and exclusion of the aneurysm, patients were treated with early ventricular drainage if hydrocephalus was present. Cranial CT scans were obtained whenever neurological deterioration raised suspicion of ischemic events or development of hydrocephalus. Patients with DCI received hypertensive hypervolemic/normovolemic therapy. In all patients with indications for monitoring of intracranial pressure or cerebrospinal fluid drainage (nϭ16), intracranial pressure was monitored by means of a ventricular drainage. Medical complications were defined according to Wartenberg et al (Table 1) . 2 Survival and global handicap at 6 and 12 months were assessed by a study nurse blinded to the immune data of the patients using the Glasgow Outcome Scale (GOS). 16 Poor outcome was defined as severe disability (GOS 3), vegetative state (GOS 2), or death (GOS 1).
Flow Cytometry and Measurement of Markers of Immunocompetence
In 16 consecutive patients, enumeration of leukocyte subsets and assessment of markers of immunocompetence in peripheral blood was performed on admission and on days 1, 2, 3, 5, 7, and 10 after hemorrhage at 8:00 AM. Leukocyte subpopulations were analyzed in EDTA-anticoagulated blood by 4-color flow cytometry on a FACSCalibur using CellQuest software (BD Biosciences), as described previously. 9 As a marker of immunocompetence, expression of human leukocyte antigen-DR on monocytes was determined by flow cytometry using a highly standardized quantitative assay (QuantiBRITE human leukocyte antigen-DR; BD Biosciences). 17 To analyze functional changes in immune responsiveness, ex vivo endotoxin-induced (lipopolysaccharide) monocytic tumor necrosis factor-␣ secretion was determined using the Milenia Ex Vivo Whole Blood Stimulation kit (Milenia Biotec) and the IMMULITE automatic chemiluminescent immunoassay (Siemens Medical Solutions) as described previously. 18 In addition, ex vivo Concanavalin A (ConA) -induced T-cell cytokine secretion was determined using the BD cytometric bead array assay (BD Biosciences) as described. 9 
Data Analysis
Between-group comparisons were performed on daily-assessed values for immune markers in peripheral blood within the first 10 days after aSAH using nonparametric methods (Mann-Whitney U ranksum test). Outcome was dichotomized into favorable (good recovery or moderate disability on the GOS) vs unfavorable outcome (severe disability, vegetative state, or death on the GOS 16 ), and survivors vs nonsurvivors. Fisher exact test was used to test for group-specific differences in patient's demographic characteristics, outcome, and incidence of infections. Differences were considered statistically significant at PϽ0.05 (SPSS 15.0; SPSS).
Results
Patient Characteristics
The characteristics of the 16 patients who met the inclusion criteria are reported in Table 2 . Seven patients remained asymptomatic, whereas 9 patients were symptomatic presenting with acute focal neurological deficits on admission (acute focal neurological deficits, all attributable to a concomitant intracerebral hemorrhage). Of these, 5 patients additionally developed DCI in the later course. Patient groups were comparable for age, gender, and duration of microdialysis monitoring, whereas, expectedly, WFNS grade, Fisher score, and duration of intensive care unit stay were significantly higher in symptomatic patients. Outcome of symptomatic aSAH patients was significantly impaired compared to the asymptomatic group (Table 2) . Five patients died within 12 months. Three of them were considered to have died of the initial hemorrhage with untreatable intracranial hypertension, and 2 patients died of extracranial causes (pneumonia followed by systemic inflammatory response syndrome and acute respiratory distress syndrome with fatal pulmonary insufficiency on day 11 after aSAH; and complication of abdominal surgery 11 months after aSAH).
Changes in Cellular Immune Markers After aSAH
In all patients, we performed detailed immune monitoring up to day 10 after aSAH to determine aSAH-induced changes in cellular immune function (Figures 1 and 2) . Symptomatic ϩ T cells, and natural killer cells as early as day 2 after aSAH, compared to asymptomatic patients. No significant group differences were observed for granulocytes, monocytes, and B lymphocytes at any time (Figure 1) . Furthermore, symptomatic patients showed a persistent reduction in human leukocyte antigen-DR expression on monocytes and monocytic tumor necrosis factor-␣ secretion after ex vivo lipopolysaccharide stimulation, whereas these parameters normalized within 3 to 5 days in asymptomatic patients (Figure 2A, B) . In addition, mitogen-induced lymphocytic interferon-␥ and IL-2 production were significantly lower in symptomatic compared to asymptomatic patients as early as day 2 after aSAH ( Figure 2C, D) . Together, these data indicate that aSAH is associated with signs of immunodepression that is more pronounced in symptomatic patients.
Infectious Complications After aSAH
There was no significant difference in the incidence of wound infections, blood stream infections, urinary tract infections, and meningitis between symptomatic and asymptomatic patients. Bacterial pneumonia, however, was significantly more frequent in symptomatic patients (nϭ6 vs nϭ0; Pϭ0.011; median onset day 3 [range, 2-8] after aSAH). As causative agents, Staphylococcus aureus, Serratia marcescens, Haemophilus influenzae, Streptococcus pneumonia, and Stenotrophomonas maltophilia were identified. Two patients died after septic shock and multi-organ failure at days 9 and 11 after aSAH, respectively. Interestingly, patients with pneumonia had significantly lower T-cell counts and lymphocytic interferon-␥ production compared to noninfected patients as early as days 1 and 2 after aSAH, respectively, ( Figure 3A , B). In addition, significant differences in lipopolysaccharideinduced tumor necrosis factor-␣ secretion and monocytic human leukocyte antigen-DR expression between patients with and without pneumonia were observed, beginning at days 3 and 5 after aSAH, respectively ( Figure 3C, D) .
Discussion
This study aimed to assess the presence of immunodepression in aSAH patients with its consequences in terms of bacterial infections complicating the clinical course. There are 2 major findings: (1) signs for aSAH-induced immunodepression occurred over all WFNS grades but persisted after day 3 only in symptomatic patients; and (2) bacterial pneumonia occurred only in symptomatic aSAH patients and might, in part, be attributable to immunodepression.
Immunodepression After aSAH
To our knowledge, this study is the first detailed investigation of markers for immunodepression in relation to cerebral metabolism and clinical complications in aSAH. Our results suggest the severity of disease combined with the clinical course to be strongly associated with the duration of immunodepression and occurrence of fever and pneumonia. In symptomatic patients, we found a persistent suppression of the cellular immune response and an impaired proinflammatory cytokine release by monocytes and lymphocytes throughout the observation period of 10 days, whereas in asymptomatic patients (all with low WFNS grades I-II, no DCI) parameters of immune competence recovered within 3 to 5 days after aSAH. This is also reflected clinically because asymptomatic patients showed Figure 1 . Course of leukocyte subsets in asymptomatic and symptomatic aneurysmal subarachnoid hemorrhage (aSAH) patients. Leukocyte counts and respective subpopulations were assessed in asymptomatic (circles; nϭ7) and symptomatic (presenting with acute focal neurological deficits; squares; nϭ9) patients at days 1 to 10 after aSAH by flow cytometry. Absolute numbers (meansϮSD) of (A) neutrophil granulocytes, (B) monocytes, (C) CD4 no signs of systemic inflammation and a lower incidence of fever as compared to the symptomatic group.
Temporary immunodepression has been already described in patients after acute traumatic brain injury, neurosurgery, and stroke. 19, 20 Comparable to our results, pronounced immunodepression and severe infections occurred in stroke patients with unfavorable clinical course. 8 Experimental and clinical studies have indicated that activation of the neurohumoral stress pathways, including the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis, plays a major role in the inhibition of immune function after acute central nervous system injury. It remains to be determined whether similar mechanisms are operational in the development of immunodepression after aSAH.
aSAH-Associated Bacterial Pneumonia
Bacterial pneumonia is not only the leading cause of severe sepsis in intensive care unit patients and the most common cause of death in stroke patients but also a well-known complication in aSAH. 21, 22 The high incidence of abnormal mental status, reduction of bulbar reflexes, dysphagia, aspiration, or mechanical ventilation for several days are considered to be major contributors to the high incidence of bacterial pneumonia after stroke. 23 It is therefore not surprising that this complication occurred only in symptomatic patients. However, recent experimental and clinical studies stress the role of an impaired immune response in addition to neurological deficits causing dysphagia for the increased susceptibility to nosocomial pneumonia in patients with acute central nervous system injury. 20, 24 In an experimental stroke model, we previously have shown that cerebral ischemia induces a rapid suppression of cellular immune responses, particularly a defective lymphocytic interferon-␥ production, which precedes the development of systemic bacterial infections within 3 days after stroke. 6 Furthermore, stroke-induced immunodepression is long-lasting and facilitates the development of severe pneumonia after aspiration of an otherwise harmless small dose of Streptococcus pneumoniae even 14 days after experimental stroke. 25 Recent evidence from clinical studies indicates that downregulation of systemic cellular immune responses, including rapid decrease in peripheral blood lymphocyte counts and functional deactivation of monocytes and interferon-␥-producing lymphocytes, also occurs in stroke patients and, further, that signs of immunodepression are more prominent in patients with infectious complications and occur before onset of these infections. 8,17,26 -28 In line with these data, we demonstrate in this study that patients with pneumonia showed significantly lower T-cell counts, reduced lymphocytic interferon-␥ secretion, and decreased monocytic release of tumor necrosis factor-␣ and surface expression of human leukocyte antigen-DR compared to patients without infectious complications. Notably, impaired cellular immune function in patients with pneumonia (particularly T-lymphopenia and defective lymphocytic interferon-␥ production) was evident as early as day 1 after aSAH. This supports the notion that immunodepression after acute central nervous system injury is an additional risk factor that increases susceptibility to infections.
Limitations and Perspectives
A major limitation of our study is the limited patient number, although it is higher or comparable to the few available studies investigating immune markers in aSAH patients (Hillman et al, nϭ14; Hanafy et al, nϭ14). 29, 30 In this context, the particularity of the present study is the unique spectrum of immune markers and functional tests performed. aSAH is a heterogeneous disease and WFNS grade was high in symptomatic patients, which limits generalizability of the results. Although our data indicate that temporary immunodepression is correlated with severity of aSAH, surgical procedures (craniotomy, clipping) may have further affected immune markers. 4 In addition, the role of endogenous stress mediators (catecholamines, glucocorticoids) and medication on immunodepression was not analyzed. Because in most patients no MRI was available, an analysis of the anatomic site of the lesion possibly related to the degree of immunodepression was not performed.
Although it is emerging that brain-immune interactions after aSAH have serious clinical implications regarding the incidence of infections, a better understanding of the immune response of this complex pathophysiological condition is necessary and may lead to effective therapeutic strategies, eliminating a major determinant of complications in aSAH patients.
Conclusion
In summary, aSAH-induced immunodepression, documented for the first time to our knowledge, occurred over all WFNS grades but persisted after day 3 only in neurologically symptomatic aSAH patients (high WFNS grade). The incidence of bacterial pneumonia after aSAH was considerably increased in symptomatic patients and might be attributable to immunodepression. Specific immunoprofiling may help to identify patients at high risk for SAH-associated infections and may allow tailored treatment to improve outcome after aSAH in the future.
